Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.62 |
| ▸ | KDR | P35968 | 7/20 | 0.61 |
| ▸ | KIT | P10721 | 6/20 | 0.61 |
| ▸ | PDGFRA | P16234 | 6/20 | 0.61 |
| ▸ | FLT4 | P35916 | 5/20 | 0.61 |
| ▸ | FLT3 | P36888 | 5/20 | 0.61 |
| ▸ | ACVRL1 | P37023 | 4/20 | 0.61 |
| ▸ | MAP2K1 | Q02750 | 4/20 | 0.61 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.61 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.61 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.61 |
| ▸ | FLT1 | P17948 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.59 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.59 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.59 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.59 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2314134 | 1.00 | OPRD1 (0.62) | OPRD1KDRKITPDGFRAFLT4 | |
| SCHEMBL16226914 | 0.85 | IDO1 (0.53) | OPRD1KDRKITPDGFRAFLT4 | |
| SCHEMBL3366320 | 0.85 | MEN1 (0.64) | OPRD1KDRKITPDGFRAFLT4 | |
| SCHEMBL638027 | 0.84 | MAOA (0.64) | KDM4ESMN1; SMN2MKNK2MAOAMAOB | |
| SCHEMBL2114985 | 0.83 | KLK7 (0.70) | OPRD1KDRKITPDGFRAFLT4 | |
| SCHEMBL2114989 | 0.83 | KLK7 (0.70) | OPRD1KDRKITPDGFRAFLT4 | |
| SCHEMBL16226082 | 0.80 | IDO1 (0.47) | OPRD1KDRKITPDGFRAFLT4 | |
| SCHEMBL846752 | 0.80 | KLK7 (0.53) | OPRD1KDRKITPDGFRAFLT4 | |
| SCHEMBL30801445 | 0.80 | CYP19A1 (0.66) | OPRD1KDRKITPDGFRAFLT4 | |
| SCHEMBL2188208 | 0.80 | KDM4E (0.53) | OPRD1KDRKITPDGFRAFLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113519842-A | Composite biological enzyme and application thereof in carrot fruit and vegetable juice | 北京牵手果蔬饮品股份有限公司 | 2021-10-22 | — | — | CN | disclosed |
| CN-113412895-A | Beverage for improving eyesight by promoting absorption and preparation method and application thereof | 黄轲 | 2021-09-21 | — | — | CN | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20090047221-A1 | COMPOUNDS AND COMPOSITIONS USEFUL IN THE TREATMENT OF NEOPLASIA | NIPRI LIMITED (GB) | 2009-02-19 | — | — | US | disclosed |
| US-20090047221-A1 | COMPOUNDS AND COMPOSITIONS USEFUL IN THE TREATMENT OF NEOPLASIA | NIPRI LIMITED (GB) | 2009-02-19 | — | — | US | disclosed |
| US-20090047221-A1 | COMPOUNDS AND COMPOSITIONS USEFUL IN THE TREATMENT OF NEOPLASIA | NIPRI LIMITED (GB) | 2009-02-19 | — | — | US | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
| EP-1807410-A1 | COMPOUNDS AND COMPOSITIONS USEFUL IN THE TREATMENT OF NEOPLASIA | NIPRI Limited (GB) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006046071-A1 | COMPOUNDS AND COMPOSITIONS USEFUL IN THE TREATMENT OF NEOPLASIA | NIPRI LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
| JP-2001064102-A | ANIMAL REPELLING MATERIAL | DAINIPPON TORYO CO LTD | 2001-03-13 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | OPRD1 107/4885KDR 2467/4885KIT 822/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | OPRD1 2509/4885KDR 2582/4885KIT 3221/4885 |
| US-20090047221-A1 | COMPOUNDS AND COMPOSITIONS USEFUL IN THE TREATMENT OF NEOPLASIA | MKI67, TP53, CCNA1 | OPRD1 3815/4885KDR 4065/4885KIT 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.